Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi Henan Cancer Hospital, Zhengzhou, Henan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Zhejiang Cancer Hospital, Hangzhou, Zhejiang Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Shanghai Chest Hospital, Shanghai